トンネル化CAR:MMP-7とOsteopontin-bの過剰発現によってCAR T細胞腫瘍の浸透を増加させる
Stacey Van Pelt1, Mark White1, Candise Tat1
1Baylor College of Medicine, Houston, TX, United States.
Cancer immunology research
|September 1, 2025
まとめ
化学抗原受容体 (CAR) T細胞療法では,細胞外マトリックス (ECM) による固体腫瘍に問題がある. この研究では,GD2. CAR T細胞におけるオステオポントン (OPN) の過剰発現は,神経芽細胞のモデルにおける腫瘍の浸透と制御を改善した.
科学分野:
- 免疫療法
- 腫瘍学
- バイオテクノロジー
背景:
- 化学抗原受容体 (CAR) T細胞治療は,血液がんでは有望だが,固体腫瘍では限られている.
- 固体腫瘍の密集した細胞外マトリックス (ECM) は,CAR T細胞の浸透を阻害し,治療の有効性に影響します.
- 神経芽細胞腫 (NB) は,GD2- CAR T細胞治療に何らかの反応を示しているが,大容量疾患のクリアランスは浸透の問題によって制限されている.
研究 の 目的:
- 固体腫瘍におけるGD2.CAR T細胞の浸透障壁を調査する.
- ECMを通して CAR T細胞の浸透を高める遺伝的変化を特定する.
- 神経芽細胞におけるGD2. CAR T細胞機能を改善するためのオステオポントン (OPN) またはMMP-7の治療可能性を評価する.
主な方法:
- GD2.CAR T細胞と他のCAR T細胞および内生性T細胞の浸透を比較した.
- 腫瘍に浸透する白血球で上調された候補遺伝子 (MMP7,SPP1/OPN) を特定するために,臨床データセットを分析した.
- 過剰発現したOPNまたはMMP-7をGD2.CAR T細胞で測定し,そのエクストラバゼーションと移動をインビトロで評価した.
- OPN-GD2.CAR T細胞治療後の神経芽細胞異種移植モデルにおける腫瘍浸透,制御,生存を評価した.
主要な成果:
- GD2.CAR T細胞は,他のT細胞と比較して独特の浸透制限を示した.
- MMP-7とOPNの過剰発現は,ECM密度の高い環境内でのCAR T細胞の動きを強化した.
- OPNまたはMMP-7の過剰発現は,神経芽細胞異種移植モデルにおける腫瘍浸透を著しく改善した.
- OPNで改変されたGD2. CAR T細胞は,マウスの腫瘍制御を改善し,生存期間を延長しました.
- OPNの過剰発現は標的外浸透を増加させたり,転移を促したりしませんでした.
結論:
- オステオポントン (OPN) とMMP-7は,固体腫瘍におけるCAR T細胞浸透を促進する有望な候補である.
- OPN修正のGD2. CAR T細胞治療は,神経芽細胞腫の安全で効果的な治療の可能性を示しています.
- この研究は,CAR T細胞を設計して,固体腫瘍におけるECMの障壁を克服するための基礎を提供します.
関連する概念動画
The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Metastasis
5.7K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.7K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
Tumor Immunotherapy
659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659


